Solid dosed SGT-003 in Phase 3 IMPACT DUCHENNE in April 2026 and scheduled an FDA Type C meeting. Its $348.9 million in cash and securities is expected to fund operations into the first half of 2028.
SLDB · Solid Biosciences Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 71%
- Last earnings
- Feb 18, 2025
- Latest filing
- 10-Q · Nov 4
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLDB
this stock
Solid Biosciences Inc.
|
$697.57M | +10.8% | -40.6% | — | 11.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 16
Solid dosed SGT-003 in Phase 3 IMPACT DUCHENNE in April 2026 and scheduled an FDA Type C meeting. Its $348.9 million in cash and securities is expected to fund operations into the first half of 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLDB | -8.6% | +5.6% | -5.0% | +0.8% | +10.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -0.1% | +14.8% | +4.2% | +9.5% | +9.7% |